Jazz and Zymeworks sign license agreement for antibody development
Jazz has entered into an exclusive licensing agreement with Zymeworks BC to develop and commercialise the latter’s Zanidatamab.
Page 11 - Rob Iannone News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Rob Iannone. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Rob Iannone Today - Breaking & Trending Today
Jazz Pharmaceuticals plc: Jazz Pharmaceuticals and Zymeworks Announce Exclusive License Agreement to Develop and Commercialize Zanidatamab, a HER2-Targeted Bispecific Antibody
Jazz to obtain exclusive development and commercialization rights in key markets including the U.S., Europe and Japan Zymeworks to receive $50 million upfront payment, a second payment
Source: finanznachrichten.de
Jazz Pharmaceuticals and Zymeworks Announce Exclusive License Agreement to Develop and Commercialize Zanidatamab, a HER2-Targeted Bispecific Antibody
Jazz to obtain exclusive development and commercialization rights in key markets including the U.S., Europe and Japan Zymeworks to receive $50 million upfront...
Source: prnewswire.com
Zymeworks stock surges 14% on license deal with Jazz for cancer drug zanidatamab
Jazz Pharmaceuticals (JAZZ) signed a licensing agreement for development and commercialization rights to Zymeworks' (ZYME) cancer drug zanidatamab in certain regions.Under the...
Source: seekingalpha.com